Continuing Education Information: Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
Katelyn Hood, PharmD, and Arpita Shah, PharmD
© 2016 Harborside Press®
The FDA approval of belinostat provides APs with an additional option for heavily pretreated patients with relapsed/refractory peripheral T-cell lymphoma who did not achieve a desirable response to traditional chemotherapy agents. Read about the drug’s mechanism of action, key trials leading to approval, potential adverse events, and important dosing and administration information.
For access to the full length article, please sign in